Wu Xiaoai, Cai Huawei, Ge Ran, Li Lin, Jia Zhiyun
Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, P.R. China.
Department of Nuclear Medicine, Fujian Medical University Union Hospital, Fuzhou, P.R. China.
Curr Neuropharmacol. 2014 Dec;12(6):551-63. doi: 10.2174/1570159X13666141204221238.
Parkinson's disease (PD) is a common progressive, neurodegenerative brain disease that is promoted by mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction in the brain. Compared with computer tomography (CT) or magnetic resonance imaging (MRI), non-invasive nuclear radiopharmaceuticals have great significance for the early diagnosis of PD due to their high sensitivity and specificity in atypical and preclinical cases. Based on the development of coordination chemistry and chelator design, radionuclides may be delivered to lesions by attaching to PD-related transporters and receptors, such as dopamine, serotonin, and others. In this review, we comprehensively detailed the current achievements in radionuclide imaging in Parkinson's disease.
帕金森病（PD）是一种常见的进行性神经退行性脑疾病，由大脑中的线粒体功能障碍、氧化应激、蛋白质聚集和蛋白酶体功能障碍引发。与计算机断层扫描（CT）或磁共振成像（MRI）相比，非侵入性核放射性药物在非典型和临床前期病例中具有高灵敏度和特异性，对帕金森病的早期诊断具有重要意义。基于配位化学和螯合剂设计的发展，放射性核素可通过附着于与帕金森病相关的转运体和受体（如多巴胺、血清素等）递送至病变部位。在本综述中，我们全面详细地阐述了帕金森病放射性核素成像的当前成果。
